222 related articles for article (PubMed ID: 30288788)
1. Evaluation of the treatment costs and duration of topical treatments for multiple actinic keratosis based on the area of the cancerization field and not on the number of lesions.
Calzavara-Pinton P; Tanova N; Hamon P
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):312-317. PubMed ID: 30288788
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the costs of topical treatments for actinic keratosis based on lesion response and the affected area.
Calzavara-Pinton P; Zane C; Arisi M; Hamon PA; Tanova NT
G Ital Dermatol Venereol; 2018 Dec; 153(6):764-775. PubMed ID: 29998712
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of topical treatments for actinic keratosis in the perspective of the Italian health care system.
Colombo GL; Chimenti S; Di Matteo S; Fargnoli MC; Frascione P; Silipo V; Peris K
G Ital Dermatol Venereol; 2010 Oct; 145(5):573-81. PubMed ID: 20930692
[TBL] [Abstract][Full Text] [Related]
4. A trial-based cost-effectiveness analysis of topical 5-fluorouracil vs. imiquimod vs. ingenol mebutate vs. methyl aminolaevulinate conventional photodynamic therapy for the treatment of actinic keratosis in the head and neck area performed in the Netherlands.
Jansen MHE; Kessels JPHM; Merks I; Nelemans PJ; Kelleners-Smeets NWJ; Mosterd K; Essers BAB
Br J Dermatol; 2020 Oct; 183(4):738-744. PubMed ID: 31961446
[TBL] [Abstract][Full Text] [Related]
5. The clinical efficacy of topical methyl-aminolevulinate photodynamic therapy in moderate to severe actinic keratoses of the face and scalp.
Kleinpenning MM; van de Kerkhof PC; Gerritsen RM
J Dermatolog Treat; 2010 Jul; 21(4):252-7. PubMed ID: 19832288
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapeutic management of actinic keratosis: focus on newer topical agents.
Samrao A; Cockerell CJ
Am J Clin Dermatol; 2013 Aug; 14(4):273-7. PubMed ID: 23640424
[TBL] [Abstract][Full Text] [Related]
7. Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy.
Neri L; Peris K; Longo C; Calvieri S; Frascione P; Parodi A; Eibenschuz L; Bottoni U; Pellacani G;
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):93-107. PubMed ID: 29920789
[TBL] [Abstract][Full Text] [Related]
8. A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.
Tolley K; Kemmett D; Thybo S; Nasr R; Smethurst H
Eur J Health Econ; 2016 Apr; 17(3):287-304. PubMed ID: 25795391
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomic analysis of the treatment of multiple actinic keratoses.
Gold MH
J Drugs Dermatol; 2008 Jan; 7(1):23-5. PubMed ID: 18246694
[TBL] [Abstract][Full Text] [Related]
10. Cost-efficacy analysis of 3% diclofenac sodium, ingenol mebutate, and 3.75% imiquimod in the treatment of actinic keratosis.
Nisticò S; Del Duca E; Torchia V; Gliozzi M; Bottoni U; Muscoli C
Int J Immunopathol Pharmacol; 2018; 32():2058738418757925. PubMed ID: 29442526
[TBL] [Abstract][Full Text] [Related]
11. Prospective, case-based assessment of sequential therapy with topical Fluorouracil cream 0.5% and ALA-PDT for the treatment of actinic keratosis.
Martin G
J Drugs Dermatol; 2011 Apr; 10(4):372-8. PubMed ID: 21455547
[TBL] [Abstract][Full Text] [Related]
12. Dermoscopy and methyl aminolevulinate: A study for detection and evaluation of field cancerization.
Rossi A; Garelli V; Pranteda G; Cardone M; Anzalone A; Fortuna MC; Di Nunno D; Mari E; De Vita G; Carlesimo M
J Photochem Photobiol B; 2016 Sep; 162():72-76. PubMed ID: 27344021
[TBL] [Abstract][Full Text] [Related]
13. Randomized clinical trial testing the efficacy and safety of 0.5% colchicine cream versus photodynamic therapy with methyl aminolevulinate in the treatment of skin field cancerization: study protocol.
Miola AC; Ferreira ER; Abbade LPF; Schmitt JV; Miot HA
BMC Cancer; 2018 Mar; 18(1):340. PubMed ID: 29587662
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Ingenol Mebutate Gel for the Treatment of Actinic Keratosis in Greece.
Athanasakis K; Boubouchairopoulou N; Tarantilis F; Tsiantou V; Kontodimas S; Kyriopoulos J
Clin Ther; 2017 May; 39(5):993-1002. PubMed ID: 28449867
[TBL] [Abstract][Full Text] [Related]
15. Real-life Data on Patient Characteristics, Cost and Effectiveness of Field-directed Treatment for Actinic Keratoses: An Observational Study.
van Rijsingen MC; Seubring I; Grutters JP; Maessen-Visch MB; Alkemade HA; van Doorn R; Groenewoud H; van de Kerkhof PC; van der Wilt GJ; Gerritsen MJ
Acta Derm Venereol; 2016 Mar; 96(3):346-50. PubMed ID: 26280988
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness and Cost-Utility Analysis of Ingenol Mebutate Versus Diclofenac 3% and Imiquimod 5% in the Treatment of Actinic Keratosis in Spain.
Elías I; Ortega-Joaquín N; de la Cueva P; Del Pozo LJ; Moreno-Ramírez D; Boada A; Aguilar M; Mirada A; Mosquera E; Gibbons C; Oyagüez I
Actas Dermosifiliogr; 2016; 107(6):498-508. PubMed ID: 27130804
[TBL] [Abstract][Full Text] [Related]
17. Topical corticosteroid has no influence on inflammation or efficacy after ingenol mebutate treatment of grade I to III actinic keratoses (AK): A randomized clinical trial.
Erlendsson AM; Karmisholt KE; Haak CS; Stender IM; Haedersdal M
J Am Acad Dermatol; 2016 Apr; 74(4):709-15. PubMed ID: 26810403
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of a film-forming medical device containing sunscreen (50+) and piroxicam 0.8% in actinic keratosis and field cancerization: a multicenter, assessor-blinded, 3 month trial.
Puviani M; Galloni C; Marchetti S; Sergio Pavone P; Lovati S; Pistone G; Caputo V; Tilotta G; Scarcella G; Campione E; Diluvio L; Garofalo V; Bianchi L; Milani M
Curr Med Res Opin; 2017 Jul; 33(7):1255-1259. PubMed ID: 28358282
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Resource Utilization and Treatment Patterns in Patients with Actinic Keratosis in the United States.
Asche CV; Zografos P; Norlin JM; Urbanek B; Mamay C; Makin C; Erntoft S; Chen CC; Hines DM; Mark Siegel D
Value Health; 2016; 19(2):239-48. PubMed ID: 27021759
[TBL] [Abstract][Full Text] [Related]
20. Field Cancerization Therapies for Management of Actinic Keratosis: A Narrative Review.
Jetter N; Chandan N; Wang S; Tsoukas M
Am J Clin Dermatol; 2018 Aug; 19(4):543-557. PubMed ID: 29582369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
